Skip to main content

Table 2 No significant nausea (NSN) rates in NEPA-treated lung and non-lung cancer patients receiving cisplatin or carboplatin in cycle 1 (efficacy population)

From: Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic

  Study 1 Study 2
NSN, % Cisplatin Cisplatin Carboplatin
Lung cancer Non-lung cancer Lung cancer Non-lung cancer Lung cancer Non-lung cancer
NEPA
(n = 109) 		PALO
(n = 42) 		NEPA
(n = 298) 		NEPA
(n = 43) 		NEPA
(n = 29) 		NEPA
(n = 79) 		NEPA
(n = 66)
Acute (0–24 h) phase 95.4 95.2 95.6 90.7 93.1 83.5 93.9
Delayed (25–120 h) phase 89.0 88.1 86.6 81.4 86.2 79.7 90.9
Overall (0–120 h) phase 87.2 88.1 84.6 81.4 82.8 79.7 89.4
  1. NEPA netupitant-palonosetron, PALO palonosetron
Back to article page